Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerBilling CodesProprietary Laboratory AnalysesCPT cpt-0502u-quantivirus-hpv-e6-e7-mrna-test-cervical-cancer
    Ask Trek AI about this page

    CPT 0502U: QuantiVirus HPV E6/E7 mRNA Test for Cervical Cancer

    CPT code 0502U is a Proprietary Laboratory Analyses (PLA) code for the QuantiVirus™ HPV E6/E7 mRNA Test (DiaCarta Inc.), a molecular diagnostic that detects high‑risk human papillomavirus by identifying E6/E7 mRNA markers in cervical cells; the service is a specialized laboratory molecular pathology test typically performed in a clinical laboratory or reference lab and reported as a positive or negative result for high‑risk HPV.

    For related coverage guidance, see recent payer policy updates: Minimal Residual Disease (MRD) Testing for Cancer, Biomarker Testing Mandate, Prenatal (Fetal) Diagnostic Testing.

    Customize your policy alerts

    Sign up for cpt 0502U policy alerts

    Get alerted when payer policies referencing 0502U are released or updated.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Table of contents

    Progress1 / 7

    Explore openpayer tools

    • Billing CodesCPT, HCPCS, DRG & more
    • Reimbursement RatesCommercial vs. Medicare rate reports
    • Facility ComparisonBeds, revenue & payer mix
    • ProvidersHospitals & facilities
    • PayersPlans & market footprint
    • Taxonomy CodesNUCC specialty codes
    • ModifiersCPT modifiers & usage
    • Prior AuthorizationPA policies by payer & drug
    • Timely FilingFiling deadlines by payer
    • Coverage CriteriaMedical necessity by payer
    • Payer ContactsClaims, PA & appeals contacts
    View all tools

    Clinical & Coding Specifications

    Clinical Context

    A typical patient is a sexually active adult woman presenting for cervical cancer screening follow-up after an abnormal Pap test or positive high-risk HPV DNA screening, or for evaluation of persistent cytologic abnormalities. The clinical workflow begins in the outpatient gynecology clinic: a clinician (OB/GYN, family medicine, or women's health nurse practitioner) collects a cervical specimen during speculum exam using a cytobrush/collection device, places the sample in appropriate transport medium, and sends it to DiaCarta Inc. or an authorized reference lab. The lab performs the QuantiVirus™ HPV E6/E7 mRNA Test (0502U) using branched-chain capture hybridization to detect E6/E7 mRNA from high-risk HPV types and reports a binary result (positive/negative) for high-risk HPV. Results are routed back to the ordering provider who documents the finding, informs the patient, and determines next steps (surveillance, colposcopy, biopsy, or treatment) based on clinical guidelines and the patient’s history. Typical site of service is outpatient ambulatory clinic, physician office, or an independent clinical laboratory performing PLA testing.

    Related CPT Codes

    CPT CodeDescriptionRelationship to This Procedure
    0502UQuantiVirus™ HPV E6/E7 mRNA Test for Cervical Cancer (Branched‑chain capture hybridization; reports positive/negative for high‑risk HPV)The primary Proprietary Laboratory Analyses (PLA) code for this specific test.
    88142Cytopathology, cervical or vaginal (e.g., Pap smear) by automated screening with manual rescreen and computer‑assisted interpretationOften performed before or alongside HPV testing for cervical cytology screening and reflex testing pathways.
    87622Infectious agent detection by nucleic acid (DNA or RNA); human papillomavirus (HPV), high‑risk types (eg, types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68), multiplex real‑time amplificationAlternative high‑risk HPV nucleic acid test commonly used in screening algorithms; may be ordered instead of or in addition to mRNA testing depending on clinical protocols.
    88305Surgical pathology, gross and microscopic examinationUsed if colposcopy with directed biopsy follows a positive 0502U result; specimens are submitted for pathologic diagnosis.
    57454Colposcopy of the cervix including upper/adjacent vagina; with biopsy(s) of the cervixDiagnostic procedure commonly performed after positive high‑risk HPV or abnormal cytology findings.

    Related Modifiers

    5 rows

    ModifierDescriptionWhen to Use
    26Modifier 26 (Professional Component) identifies and bills only the professional portion of a split service — the physician’s interpretation, report, and medical judgment — when the technical…- Use CPT Modifier -26 when you are billing only the professional component (PC) of a split‑bill eligible service—i.e., you performed the physician interpretation, medical judgment and prepared a…
    52Modifier ‑52 (Reduced Services) indicates that a service or procedure was partially reduced or omitted at the provider’s discretion, allowing reporting of the basic procedure number with a qualifier…- Use modifier -52 when a physician or qualified health professional electively reduces or omits part of a procedure or service (for example, performing fewer required views or omitting a portion of…
    53Modifier 53 (Discontinued Procedure) signals that a surgical or diagnostic service was begun by the physician but terminated because of extenuating circumstances that threatened the patient’s…- Use modifier -53 when a physician/qualified healthcare professional has started a surgical or diagnostic procedure (e.g., anesthesia administered, incision or scope insertion) and then discontinues…
    56Modifier ‑56 indicates the reporting provider furnished only the preoperative management for a surgical procedure and did not perform the intraoperative or postoperative care. It is used in…- Use Modifier -56 when a provider performs only the preoperative management in a split‑care situation (one physician manages preop care while a different physician performs the intraoperative…
    95Modifier 95 indicates that a service was provided via synchronous, real‑time audio‑video telehealth rather than in‑person. Per CMS, AAPC and professional associations, append modifier 95 to claim…- Use modifier 95 to indicate a service was furnished via synchronous, real‑time audiovisual telehealth (a live audio‑video conference between patient and provider) rather than in‑person. - Pair…

    Related Provider Taxonomies

    8 rows

    Taxonomy Code
    207V00000X
    207Q00000X
    363LF0000X
    207PT0002X
    152WL0500X
    364SE1400X
    235500000X
    261QP2000X

    Related ICD-10-CM Codes

    26 rows

    ICD-10-CM CodeDescription
    C53.0Malignant neoplasm of endocervix
    C53.1Malignant neoplasm of exocervix
    C53.9Malignant neoplasm of cervix uteri, unspecified
    D06.0Carcinoma in situ of endocervix
    D06.1Carcinoma in situ of exocervix
    D06.9Carcinoma in situ of cervix, unspecified
    N72Inflammatory disease of cervix uteri
    N73.6Female pelvic peritoneal adhesions (postinfective)
    N76.0Acute vaginitis
    N76.1Subacute and chronic vaginitis

    Showing 1–10 of 26

    Related Payer Policy Updates

    Specialty: Genetic & Molecular Testing1 / 3

    10 rows

    PolicyPayerEffective Date
    Minimal Residual Disease (MRD) Testing for Cancerregence2027-01-01
    Biomarker Testing MandateBlue Cross Blue Shield - Rhode Island2027-01-01
    Prenatal (Fetal) Diagnostic TestingBlue Cross Blue Shield - Rhode Island2027-01-01
    Oral Cancer Screening and TestingOscar Health2027-01-01
    RTM Testing for Alpha-1 Antitrypsin DeficiencyOscar Health2027-01-01
    Cytochrome P450 Genotype-Guided Treatment Strategy Corporate Medical Policybcbsvermont2027-01-01
    Cytochrome P450 Genotypingblue cross blue shield - tennessee2026-12-31
    Polygenic Risk ScoreBlue Cross Blue Shield - Rhode Island2026-12-01
    Gene Expression Profiling for Cutaneous MelanomaBlue Cross Blue Shield - Rhode Island2026-12-01
    Chromosomal Microarray Testing for the Evaluation of Pregnancy Lossblue_shield_of_california2026-11-01

    Related Codes

    CPT-0001U-PRECISETYPE-HEA-MULTIPLEX-RBC-ANTIGEN-GENOTYPING

    CPT 0001U: PreciseType HEA Erythrocyte Antigen Genotyping

    CPT-0002U-POLYPDX-URINE-METABOLOMIC-ASSAY-ADENOMATOUS-POLYP-RISK

    CPT 0002U: PolypDX™ Urine Metabolomic Risk Assay

    CPT-0003U-OVAR-A-NEXT-GENERATION-OVARIAN-CANCER-RISK-ASSAY

    CPT 0003U: Overa (MIA2G) Ovarian Cancer Risk Assay

    CPT-0005U-PROSTATE-EXOSOMEDX-INTELLISCORE-GENE-EXPRESSION-URINE-TEST

    CPT 0005U: ExosomeDx Prostate (IntelliScore) urine gene expression test

    CPT-0007U-TOXPROTECT-URINE-DRUG-SCREEN-WITH-DNA-AUTHENTICATION

    CPT 0007U: ToxProtect Urine Drug Screen With DNA Authentication

    CPT-0008U-H-PYLORI-ANTIBIOTIC-RESISTANCE-SEQUENCING-PANEL

    CPT 0008U: H. pylori Antibiotic Resistance Gene Panel

    CPT-0009U-DEPARRAY-HER2-FISH-TUMOR-CELL-ISOLATION

    CPT 0009U: DEPArray HER2 Tumor‑Cell Isolation with FISH Analysis

    CPT-0010U-BACTERIAL-TYPING-WHOLE-GENOME-SEQUENCING-MAYO-CLINIC

    CPT 0010U: Bacterial Typing by Whole Genome Sequencing, Mayo Clinic

    CPT-0011U-CORDANT-CORE-ALGORITHMIC-ORAL-FLUID-DRUG-TEST

    CPT 0011U: Oral Fluid Drug Test with Algorithmic Steady‑State Comparison

    CPT-0016U-BCR-ABL1-MAJOR-MINOR-FUSION-TRANSCRIPT-TESTING

    CPT 0016U: BCR–ABL1 Major and Minor Breakpoint Fusion Transcripts

    Showing 1–10 of 536

    • More pages

    Frequently Asked Questions

    References

    1. 1.CPT® Codes and Descriptions. AAPC. Retrieved Aug 11, 2026.Maintains the CPT code set's official descriptions and guidelines, licensed from the American Medical Association, used as the definitional source for CPT codes on this page.
    2. 2.HCPCS Quarterly Update. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's quarterly release of HCPCS Level II codes and short/long descriptors, the source for HCPCS code definitions and update history.
    3. 3.ICD-10-CM Full Code List. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's complete ICD-10-CM diagnosis code list, used to cross-reference diagnosis codes associated with this procedure or service.
    Published by

    Trek Health powers OpenPayer with a leading commercial payer intelligence platform, seamlessly converting fragmented payer data into actionable insights for provider organizations.

    Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.